Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium

Transplantation

Volumn 61, Issue 8, 1996, Pages 1241-1249

  Diamond, Lisa E ^a   McCurry, Kenneth R ^b   Martin, Michael J ^a   McClellan, Steven B ^a   Oldhm, Elizabeth R ^a   Platt, Jeffrey L ^b   Logan, John S ^a  

^a Nextran   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BABOON; COMPLEMENT DEPENDENT CYTOTOXICITY; ENDOTHELIUM; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SPECIES DIFFERENCE; SWINE; TRANSGENIC ANIMAL; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD59; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM; GENE TRANSFER TECHNIQUES; HEART TRANSPLANTATION; HUMANS; MYOCARDIUM; PAPIO; SWINE;

EID: 0030007827     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199604270-00021     Document Type: Article

References (54)

1. Evans, RW. Executive summary; The National Cooperative Transplantation Study. Seattle, WA: BHARC, 1991.
2. Ye Y, Niekrasz M, Kosanke S, et al. The pig as a potential organ donor for man. Transplantation 1994; 57: 694.
3. Calne, RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550.
4. Rose AG, Cooper DKC, Human PA, Reichenspurner H, Reichart B. Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J Heart Lung Transplant 1990; 10: 223.
5. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
6. Chartrand C, O'Regan S, Robitaille P, Pinto-Blonde M. Delayed rejection of cardiac xenografts in C6-deficient rabbits. Immunology 1979; 38: 245.
7. Brauer RB, Baldwin WM III, Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 7240.
8. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967; 5: 1296.
9. Levanthal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
10. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
11. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review in progress. Immunol Today 1990; 11: 450.
12. Shin M, Hansch GM, Hu VW, Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol 1986; 136: 1777.
13. Schonermark S, Rauterberg EW, Shin ML, Loke S, Roelke D, Hansch GM. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136: 1772.
14. Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991; 146: 2345.
15. Hansch GM, Hammer GH, Vanguri P, Shin ML. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 1981; 78: 5118.
16. van den Berg CW, Morgan BP. Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol 1994; 152: 4095.
17. Kennedy SP, Rollins SA, Burton W, et al. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 1994; 57: 1494.
18. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
19. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478.
20. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), and 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalyzed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1.
21. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Medicine 1995; 1: 423.
22. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59: 1177.
23. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytoxicity by decay accelerating factor: Potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530.
24. Diamond LE, McCurry KR, Oldham ER, et al. Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. Transplantation Immunol 1995; 3: 305.
25. Wall RJ, Pursel VG, Hammer RE, Brinster RL. Development of porcine ova that were centrifuged to permit visualization of pronuclei and nuclei. Biol Reprod 1985; 32: 645.
26. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
28. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984; 81: 1991.
29. Feinberg AP, Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6.
30. Davies A, Simmons DL, Hale G, et al. CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170: 637.
31. Jaffe EA, Nachman RL, Becker GC, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clinical Invest 1973; 52: 2744.
32. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated low density lipoprotein. J Cell Biology 1984; 99: 2034.
33. Alexandre GPJ, Squifflet JP, DeBruyere M, et al. Splenectomy as a prerequisiste for successful human ABO-incompatible renal transplantation. Transpl Proc 1985; 27: 138.
34. Cooper DKC, Human PA, Lexer G, et al. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988; 7: 238.
35. Michler RE, McManus RP, Smith CR, Sadeghi AN, Rose EA. Technique for primate heterotopic cardiac xenotransplantation. J Medical Primatology 1985; 14: 357.
36. Falk RI, Dalmasso AP, Kim Y. Neoantigen of the polymerized ninth component of complement characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983; 72: 560.
37. Platt JL, LeBien TW, Michael AF. Interstitial mononuclear cell populations in renal graft rejection: identification by monoclonal antibodies in tissue sections. J Exp Med 1982; 155: 17.
38. Logan JS, Martin MJ. Transgenic swine as a recombinant production system for human hemoglobin. Methods Enzymol 1994; 231: 435.
39. Tone M, Walsh LA, Waldmann H. Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. J Mol Biol 1992; 227: 971.
40. Meri S, Waldmann H, Lachman PJ. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991; 65: 532.
41. Kaplon RJ, Michler RE, Xu H, Kwiatkowski PA, Edwards NM, Platt JL. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1994; 59: 1.
42. Funabashi K, Okada N, Matsuo S, Yamamoto T, Morgan BP, Okada H: Tissue distribution of complement regulatory membrane proteins in rats. Immunology 1994; 81: 444.
43. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65: characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 1993; 151: 4295.
44. Walsh LA, Tone M, Waldmann H. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur J Immunol 1991; 21: 847.
45. Charreau B, Cassard A, Tesson L, et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 1994; 11: 1222.
46. Zhao J, Rollins SA, Maher SE, Bothwell ALM, Sims PJ. Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection agsinst the membrane attack complex of human complement. J Biol Chem 1991; 266: 13418.
47. Somerville CA, Kyriazis AG, McKenzie A, Allison J, Pearse MJ, D'Apice AJF. Functional expression of human CD59 in transgenic mice. Transplantation 1994; 58: 1430.
48. Kooyman DL, Byrne GW, McClellan S, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269: 89.
49. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay accelerating factor, in transgenic pigs. Transplantation 1995; 59: 1235.
50. Chopek MW, Simmons RL, Platt JL. ABO-incompatible renal transplantation: initial immunopathologic evaluation. Transplant Proc 1987; 19: 4553.
51. Alexandre GPJ, Squifflet JP, DeBruyere, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538.
52. Palmer A, Welsh K, Gjorstrup P, Taube D, Bewick M, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
53. Platt JL, Dalmasso AP, Lindman BJ, Ihrcke N, Bach FH. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 1991; 21: 2887.
54. Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995; 181: 21.